Tuesday, April 04, 2017 11:04:55 AM
a.
General
Orgenesis Inc. (the “Company”) was incorporated in the state of Nevada on June 5, 2008, under the name Business Outsourcing Services, Inc. Effective August 31, 2011, the Company completed a merger with its subsidiary, Orgenesis Inc., a Nevada corporation which was incorporated solely to effect a change in its name. As a result, the Company changed its name from “Business Outsourcing Services, Inc.” to “Orgenesis Inc.” The consolidated financial statements include the accounts of Orgenesis Inc., its wholly-owned subsidiaries MaSTherCell S.A (the “MaSTherCell”), its Belgian based subsidiary and a contract development manufacturing organization, or CDMO (see also note 3), specialized in cell therapy development for advanced medicinal products; Orgenesis SPRL (the “Belgian Subsidiary”), a Belgian based subsidiary which is engaged in development and manufacturing activities together with clinical development studies in Europe, and later on to be the Company’s center for activities in Europe; Orgenesis Maryland Inc. (the “U.S. Subsidiary”) a Maryland corporation, and Orgenesis Ltd. an Israeli corporation.
The Company is a regenerative therapy company with expertise and experience in cell therapy development and manufacturing.
The Company’s cell therapy technology derives from published work of Prof. Sarah Ferber, our Chief Science Officer and a researcher at Tel Hashomer Medical Research (“THM”), a leading medical hospital and research center in Israel, who established a proof of concept that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and transdifferentiating (converting) them into “pancreatic beta cell-like” insulin-producing cells. Its development activities with respect to cell-derived and related therapies, which are conducted through Orgenesis Ltd. (the “Israeli Subsidiary”), have, to date, been limited to laboratory and preclinical testing.
Recent ORGS News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 12:30:47 PM
- Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia • GlobeNewswire Inc. • 08/29/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:05:13 PM
- Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally • GlobeNewswire Inc. • 08/14/2024 12:30:00 PM
- Orgenesis Provides Second Quarter 2024 Business Update • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2024 03:25:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/14/2024 12:45:29 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/14/2024 04:15:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:05:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/06/2024 08:05:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 10:14:05 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/24/2024 01:16:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:00:31 PM
- Orgenesis Provides Business Update for the First Quarter of 2024 • GlobeNewswire Inc. • 05/21/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2024 08:01:42 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 08:01:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 07:28:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/06/2024 07:26:43 PM
- Orgenesis Provides Year End Business Update • GlobeNewswire Inc. • 04/15/2024 09:07:16 PM
- Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility • GlobeNewswire Inc. • 04/10/2024 04:00:00 PM
- Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference • GlobeNewswire Inc. • 03/18/2024 12:30:00 PM
- Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes • GlobeNewswire Inc. • 03/13/2024 12:30:00 PM
- Orgenesis Inc. Announces $2.3 Million Private Placement • GlobeNewswire Inc. • 03/04/2024 01:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM